SCHEMBL17034747

SCHEMBL17034747

CCOC(=O)CC(=O)COC1CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.42
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
NAMPT P43490 1/20 0.36
MGAM O43451 1/20 0.36
GAA P10253 1/20 0.36
SI P14410 1/20 0.36
MGAM2 Q2M2H8 1/20 0.36
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
TSHR P16473 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
EPHX1 P07099 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ADORA1 P30542 1/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120311 0.89 NR1H2 (0.46) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL31646642 0.88 NR1H2 (0.44) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL25122920 0.83 NR1H2 (0.50) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL18334523 0.82 GAA (0.41) MGAMGAASIMGAM2KMT2A
SCHEMBL27359011 0.82 NR1H2 (0.42) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL21063433 0.81 NR1H2 (0.47) NR1H2NAMPTMGAMGAASI
SCHEMBL15885931 0.80 NR1H2 (0.48) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL13677268 0.80 NR1H2 (0.53) NR1H2PRMT5WDR77NAMPTKMT2A
SCHEMBL20129208 0.80 NR1H2 (0.40) NR1H2PRMT5WDR77KMT2AALDH1A1
SCHEMBL21063448 0.79 NR1H2 (0.45) NR1H2NAMPTMGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
EP-3109239-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-12-28 EP disclosed
WO-2015125786-A1 AMINOPYRAZOLONE DERIVATIVE 第一三共株式会社 2015-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE ATAD5, ATP1A1, TIPRL NR1H2 3272/4885PRMT5 938/4885WDR77 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.